Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem)

British Journal of Dermatology

Volumn 152, Issue 4, 2005, Pages 650-657

  Rosatelli, T B ^a   Roselino, A M ^a   Dellalibera Joviliano, R ^a   Reis, M L ^a   Donadi, Eduardo A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Fogo selvagem; Kallikreins; Kininase II; Kininogens; Kinins; Pemphigus foliaceus

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; LOW MOLECULAR WEIGHT KININOGEN; NIKOLSKY PHENOMENON; PLASMA KALLIKREIN; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLISTER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; MALE; PATHOGENESIS; PEMPHIGUS FOLIACEUS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SALIVA LEVEL; SKIN INFLAMMATION; SKIN MANIFESTATION; URINE LEVEL;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; KALLIKREINS; KININOGENS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PEMPHIGUS; PEPTIDYL-DIPEPTIDASE A; PLASMA KALLIKREIN; SALIVA; TISSUE KALLIKREINS;

EID: 17644374165     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06427.x     Document Type: Article

References (46)

1. Bhoola ED, Figueroa CD, Whorty K. Bioregulation of kinins kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44:1-80.
2. Colman RW, Pixley RA, Najamunnisa S et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100:1481-7.
3. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997; 10:3819-43.
4. Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cell membranes. Immunopharmacology 1999; 43:109-14.
5. Blais C Jr, Marceau F, Rouleau JL et al. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000; 21:1903-40.
6. Kitchens CS. The contact system. Arch Pathol Lab Med 2002; 126:1382-6.
7. Mahdi F, Madar ZS, Figueroa CD et al. Factor XII interacts with the multiproteln assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99:3585-96.
8. Fernando LP, Natesan S, Joseph K et al. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb Haemost 2003; 90:787-95.
9. Schmaier AH, Wahl R, Fisher SJ et al. The pharmacokinetics of the kininogens. Thromb Res 1998; 92:293-7.
10. Schremmer-Danninger E, Heinz-Erian P, Topfer-Petersen E et al. Autoradiographic localization and characterization of bradykinin receptors in human skin. Eur J Pharmacol 1995; 283:207-16.
11. Komatsu N, Takata M, Otsuki N. et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003; 121:542-9.
12. Schermmer-Danninger E, Hermann A, Fink E. Identification and occurrence of mRNAs for components of the kallikrein kinin system in human skin and in skin diseases. Immunopharmacology 1999; 43:287-91.
13. Chiossi MP, Roselino AMF. Endemic pemphigus foliaceus (fogo selvagem): a series from the Northeastern region of the state of São Paulo, Brasil, 1973-1998. Rev Inst Med Trop São Paulo 2001; 43:59-62.
14. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964; 117:505-10.
15. Stanley JR, Klaus-Kovtun V, Sampaio SAP. Antigenic specificity of fogo selvagem autoantibodies is similar to North American pemphigus and distinct from pemphigus vulgaris autoantibodies. J Invest Dermatol 1986; 87:197-201.
16. Stanley JR, Nishikawa T, Diaz LA et al. Pemphigus: is there another half of the story? J Invest Dermatol 2001; 116:489-90.
17. Grando AS, Pittelkow MR, Shultz LD et al. Pemphigus: an unfolding story. J Invest Dermatol 2001; 117:990-5.
18. Zeoti DM, Figueiredo JF, Chiossi MP et al. Serum cytokines in Brazilian patients with pemphigus foliaceus. Braz J Med Biol Res 2000; 33:1065-8.
19. Barker JN, Mitra RS, Griffiths CE et al. Keratinocytes as initiators of inflammation. Lancet 1991; 337:211-14.
20. Tiffany CW, Burch RM. Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett 1989; 247:189-92.
21. Ferreira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 1993; 110:1227-31.
22. D'Auria L, Bonifati C, Mussi A et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumor necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997; 8:383-7.
23. Hunziker T, Vassali JD. Plamin induces acantholysis in skin organ cultures. Arch Dermatol Res 1987; 279:341-6.
24. Morioka S, Lazarus GS, Jensen PJ. Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. J Invest Dermatol 1987; 89:474-7.
25. Anhalt GJ, Patel HP, Labib RS et al. Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis. J Immunol 1986; 136:113-17.
26. Diaz LA, Roscoe JT, Eaglstein NF et al. Human pemphigus autoantibodies are pathogenic to squamous epithelium. Ann NY Acad Sci 1986; 475:181-91.
27. Diaz LA, Sampaio SA, Rivitti EA et al. Endemic pemphigus foliaceus (fogo selvagem). II. Current: and historic epidemiological studies. J Invest Dermatol 1989; 92:4-12.
28. Diniz CR, Carvalho IFA. Micromethod of determination of bradykininogen under several conditions. Ann NY Acad Sci 1963; 104:7-89.
29. Majima M, Katori M, Ogino M et al. Failure of endogenous blood kinin levels elevated by captopril to induce hypotension in normotensive and hypertensive rats: a study using a newly developed ELISA for kinin. Biomed Res 1996; 17:15-25.
30. Rothschild AM, Boden G, Colman RW. Kininogen changes in human plasma following a test meal or insulin administration. Am J Physiol 1996; 270:H1071-7.
31. De La Cadena RA, Scott CF, Colman RW. Evaluation of microassay for human plasma prekallikrein. J Lab Clin Med 1987; 109:601-7.
32. Amundsen E, Putter J, Frieberger P et al. Methods for the determination of glandular kallikrein by means of chromogenic tripeptidase substrate. Adv Exp Med Biol 1979; 120A:83-95.
33. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20:1637-48.
34. Dellalibera-Joviliano R, Reis ML, Donadi EA. Elevated plasma levels of kininogens and plasma kallikrein in patients with systemic lupus erythematosus. Eur J Pharmaceut Sci 2001; 13:S81.
35. Grando SA, Glukhenkii BT, Kostromin AP et al. The role of kallikrein-kinin system compoments in the pathogenesis of bullous skin lesions in pemphigus and pemphigoid. Vopr Med Khim 1990; 36:23-7.
36. Colman RW. Biologic activities of the contact factors in vivo-potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost 1999; 82:1568-77.
37. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70:1-15.
38. Kaplan AP, Joseph K, Shibayama Y et al. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol 1997; 66:225-72.
39. Hashimoto K, Shafran KM, Webber GS et al. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 1983; 1:259-72.
40. Reinartz JJ, Naher H, Mai H et al. Plasminogen activation in lesional skin of pemphigus vulgaris type Neumann. Arch Dermatol Res 1993; 284:432-9.
41. Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol 1999. 113:22-5.
42. Feliciani C, Toto P, Wang B et al. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003; 12:466-71.
43. Dellalibera-Joviliano R, Reis ML, Donadi EA et al. Kinin system in lupus nephritis. Int Immunopharmacol 2001; 1:889-96.
44. Rivitti EA, Sanches JA, Miyauchi LM et al. The Cooperative Group for Fogo Selvagem: pemphigus foliaceus antibodies bind both epidermis and squamous mucosal epithelium, but tissue injury is detected only in the epidermis. J Am Acad Bermatol 1994; 31: 954-8.
45. Shirakata Y, Amagai M, Hanakawa Y et al. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 1998; 110:76-8.
46. Hayashi R, Yamashita N, Matsui S et al. Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblaSts through ERK- and p38 MAPK-dependent mechanisms. Eur Respir J 2000; 16:452-8.